NRx Pharmaceuticals Advances Ketamine Approval, Secures DARPA Funding for Depression Trial — NRx Pharmaceuticals, Inc.

Event summary

Completed first-cycle FDA review of preservative-free ketamine ANDA with no drug-related major deficiencies; sole remaining item submitted to FDA.
Initiated commercial-scale manufacturing of preservative-free ketamine, building a launch stock of 5 million doses for 2026 commercialization.
Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS, with anticipated non-dilutive funding exceeding $11.5 million.
Closed a $22.3 million public offering of common stock, with existing cash expected to fund operations for at least one year.
Appointed Glenn Tyson as Chief Commercial Officer and retained a commercial launch team for preservative-free ketamine.

The big picture

NRx Pharmaceuticals is making significant strides in advancing its preservative-free ketamine toward FDA approval and commercialization, positioning itself as a key player in the mental health sector. The company's strategic partnership with DARPA for the SPARC-TMS trial and its investment in Geneuro, Inc. highlight its commitment to innovation and expansion into new markets. With a strengthened balance sheet and a focus on government-funded initiatives, NRx is poised to capitalize on the growing demand for effective treatments for depression and other central nervous system disorders.

What we're watching

Regulatory Approval: Whether the FDA will approve the preservative-free ketamine ANDA by the end of 2026, clearing the path for commercialization.
Market Expansion: The pace at which NRX-101 gains traction in the treatment-resistant depression market following the SPARC-TMS trial results.
Financial Sustainability: How NRx will manage its cash position and operational costs to ensure funding for at least one year, as projected.